Deciphering the molecular impact of ALDH5A1 missense variants in succinic semialdehyde dehydrogenase deficiency through combined in vitro and in silico approaches
6 affiliations
- 1Department of Neuroscience, Biomedicine and Movement Sciences, University of Verona
- 2Child Neurology Unit, Vittore Buzzi Children’s Hospital
- 3Radiology Unit, IRCCS, Azienda Ospedaliera Universitaria di Bologna
- 4Medical Genetics Laboratory, Clinical Pathology Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico
- 5Department of Neurology, Boston Children’s Hospital, Harvard Medical School
- 6Institute of Biochemistry, Medical Faculty, University of Giessen
Abstract
Succinic semialdehyde dehydrogenase is a key enzyme involved in the catabolism of g-aminobutyric acid. Biallelic variants in the ALDH5A1 gene cause a rare monogenic neurometabolic disorder, SSADH deficiency, characterized by a total or partial enzyme loss-of-function. Patients present symptoms from infancy on and mainly show developmental delay and intellectual disabilities, with seizures and/or autistic spectrum disorders as the main distinctive traits associated with the severe forms of the disorder. A valuable instrument to interpret variant function is provided by bioinformatic tools that are based on evolutionary and structural data. However, the results need to be complemented by other experimental approaches to dissect the molecular basis for the defect and be supportive of the clinical phenotype of patients. Here, we validate a bioinformatic prediction of loss-of-function using two recombinant enzyme variants and/or transient transfection in a ALDH5A1 knockout HEK-293T cell model. These SSADH protein variants are synthesized by two functionally hemizygous SSADH deficiency patients. The known loss-of-function p.Gly176Arg variant was predicted by bioinformatic analyses to affect oligomerization. Indeed, we demonstrate that the variant acquires a tetrameric altered structure, possibly responsible for the loss-of-function. The pathogenicity of the new p.Pro234Ser variant is mainly due to its failure to reach the mature form, possibly due to its intrinsic instability rather than a defect in the maturation apparatus, thus preventing a correct folding process. Altogether, we provide evidence that combining recombinant protein studies with structural predictions can offer valuable insights into loss-of-function, which is essential for precision therapy.
Related
- OP–137 Pediatric succinic semialdehyde dehydrogenase deficiency: clinical spectrum and treatment responses
- AI-Driven Multi-Omics Approaches for Deciphering Small-Cell Lung Cancer Heterogeneity Using Nucleic-Acid-Based Features
- A Homozygous Missense Variant in DCLK2 as a Potential Modifier of Disease Severity in PDHA1-Associated Primary Pyruvate Dehydrogenase Complex Deficiency
- Disconnect Between Succinate, Succinyl-CoA, and Histone Succinylation in Cells and Gastrointestinal Stromal Tumors with Succinate Dehydrogenase Deficiency
- Succinate Dehydrogenase in Lung Cancer: from Molecular Mechanisms to Clinical Implications.
BibTeX
@article{spagnoli2026deciphering,
title = {{Deciphering the molecular impact of ALDH5A1 missense variants in succinic semialdehyde dehydrogenase deficiency through combined in vitro and in silico approaches}},
author = {Giulia Spagnoli and Samuele Cesaro and Cristian Andres Carmona Carmona and Davide Tonduti and Fabio Bruschi and Valentina Belacchi and Stefania Paganini and Itay Tokatly-Latzer and Phillip L. Pearl and Giovanni Bisello and Miroslava Didiasova and Ritva Tikkanen and Mariarita Bertoldi},
journal = {Scientific Reports},
year = {2026},
month = jul,
doi = {10.1038/s41598-026-62784-w},
url = {https://doi.org/10.1038/s41598-026-62784-w},
note = {CC BY},
}
RIS
TY - JOUR
TI - Deciphering the molecular impact of ALDH5A1 missense variants in succinic semialdehyde dehydrogenase deficiency through combined in vitro and in silico approaches
AU - Giulia Spagnoli
AU - Samuele Cesaro
AU - Cristian Andres Carmona Carmona
AU - Davide Tonduti
AU - Fabio Bruschi
AU - Valentina Belacchi
AU - Stefania Paganini
AU - Itay Tokatly-Latzer
AU - Phillip L. Pearl
AU - Giovanni Bisello
AU - Miroslava Didiasova
AU - Ritva Tikkanen
AU - Mariarita Bertoldi
PY - 2026
DA - 2026/07/01
JO - Scientific Reports
DO - 10.1038/s41598-026-62784-w
UR - https://doi.org/10.1038/s41598-026-62784-w
AB - Succinic semialdehyde dehydrogenase is a key enzyme involved in the catabolism of g-aminobutyric acid. Biallelic variants in the ALDH5A1 gene cause a rare monogenic neurometabolic disorder, SSADH deficiency, characterized by a total or partial enzyme loss-of-function. Patients present symptoms from infancy on and mainly show developmental delay and intellectual disabilities, with seizures and/or autistic spectrum disorders as the main distinctive traits associated with the severe forms of the disorder. A valuable instrument to interpret variant function is provided by bioinformatic tools that are based on evolutionary and structural data. However, the results need to be complemented by other experimental approaches to dissect the molecular basis for the defect and be supportive of the clinical phenotype of patients. Here, we validate a bioinformatic prediction of loss-of-function using two recombinant enzyme variants and/or transient transfection in a ALDH5A1 knockout HEK-293T cell model. These SSADH protein variants are synthesized by two functionally hemizygous SSADH deficiency patients. The known loss-of-function p.Gly176Arg variant was predicted by bioinformatic analyses to affect oligomerization. Indeed, we demonstrate that the variant acquires a tetrameric altered structure, possibly responsible for the loss-of-function. The pathogenicity of the new p.Pro234Ser variant is mainly due to its failure to reach the mature form, possibly due to its intrinsic instability rather than a defect in the maturation apparatus, thus preventing a correct folding process. Altogether, we provide evidence that combining recombinant protein studies with structural predictions can offer valuable insights into loss-of-function, which is essential for precision therapy.
SN - 2045-2322
ER -